HTA and Appropriate Drug Pricing Worldwide

The August 2011 issue of Health Affairs featured four articles on how and why pricing for pharmaceuticals differs from one country to another. The OHE’s Prof Adrian Towse co-authored the lead article with Prof Patricia Danzon from the Wharton School and Dr Andrew Mulcahy of RAND.

The August 2011 issue of Health Affairs featured four articles on how and why pricing for pharmaceuticals differs from one country to another. The OHE’s Prof Adrian Towse co-authored the lead article with Prof Patricia Danzon from the Wharton School and Dr Andrew Mulcahy of RAND.  In 'Setting Cost-Effectiveness Thresholds as a Means to Achieve Appropriate Drug Prices in Rich and Poor Countries’, the authors examine what price differences exist, the factors that produce them, the implications for access to care and innovation, and what measures might be taken to produce appropriate price differences that benefit both consumers and manufacturers.

A summary of an earlier version this article appears in a recent OHE News blog post.

Danzon, P.M., Towse, A. and Mulcahy, A.W. (2011) Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries. Health Affairs. 30(8), 1529-153.